Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation
暂无分享,去创建一个
D. Niederwieser | U. Platzbecker | S. Schwind | M. Bill | D. Backhaus | M. Jentzsch | J. Grimm | D. Brauer | Karoline Goldmann | Julia Schulz | Rosmarie Pointner